BioSpace News Archive

CEL-SCI Corporation announced the Company’s Chief Scientific Officer, Dr. Eyal Talor, delivered a presentation titled “Neoadjuvant Immunotherapy for Head and Neck Cancer: Low Tumor PD-L1 Expression - IT-MATTERS – RCT” at the International Drug Discovery Science & Technology 20th Annual Congress in Budapest, Hungary on Tuesday, June 18, 2024.

Iambic Therapeutics today announced the closing of an oversubscribed $50 million extension to its Series B financing.

Shuttle Pharmaceuticals Holdings, Inc., a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy, announced the appointment of Timothy Lorber, CPA, as the Company Chief Financial Officer.

Singleron Biotechnologies announced a partnership with the Human Cell Atlas (HCA) to help accelerate the adoption of single cell sequencing globally.

Enlaza Therapeutics, the first covalent biologic platform company, today announced the appointment of Dr. Jeffrey Leiden, Executive Chairperson of Vertex Pharmaceuticals, as a key advisor to the company.

Praia Health, a consumer platform for delivering individualized health solutions at scale, announced today a new partnership with CLEAR, the secure identity company, to enhance identity verification processes for health systems.

Applied DNA Sciences, Inc. announced that its molecular diagnostics subsidiary, Applied DNA Clinical Labs, LLC, will utilize the GenXys Health Care Systems suite of clinical decision support software for interpretation and reporting of ADCL’s New York State Department of Health-approved TR8™ pharmacogenomic test.

Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado.

Nortech Systems Incorporated, a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical, aerospace & defense and industrial markets, announced the addition of Debarati Sen to the Company’s Board of Directors.

Lexaria Bioscience Corp. which will evaluate various DehydraTECH-GLP-1 formulations and other treatments with efficacy objectives of weight loss, blood sugar reduction, and more.